

Special Issue

Pharmacokinetics and Pharmacodynamics of Antibacterial and Antivirulence Drugs

Message from the Guest Editor

In 2017, the WHO published a list of bacteria, including but not limited to the so-called ESKAPE pathogens, for which research of new antibiotics is of critical or high priority as a result of increasing antimicrobial resistance. Currently, less than 50 new antibacterial compounds have been investigated in clinical trials. This highlights that compounds with novel mechanisms of action are desperately needed. To enable translation from bench to bedside, novel compounds must first prove that they reach their target site, and that they are effective under in vitro and in vivo infection conditions. In addition to novel treatment options, more sophisticated treatment regimens of current antibacterial agents can help to lower the risk of rapid emergence of antimicrobial resistance. Therefore, the main goal of this Special Issue is to present contributions of novel approaches to fighting antimicrobial resistance as well as strategies to ameliorate current treatment regimens in human medicine.

Guest Editor

Dr. Katharina Rox
Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany

Deadline for manuscript submissions

closed (31 July 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/117410

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)